A Phase 3 interventional study of nilotinib and imatinib in Chronic Myelogenous Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 56 sites in 12 countries. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-11-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 12th largest by enrollment, is one of 8 that started in 2009, is one of 15 in phase 3, and was the 15th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 8 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 191 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 20th largest by enrollment of the 63 interventional ones that give a count, is one of 5 that started in 2009, is one of 19 in phase 3, and was the 29th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
There is no available data on the clinical benefit of dose escalation for patients with suboptimal response to imatinib, and patients may still improve their response with continuation of therapy at the standard dose as shown in the IRIS trial after 5 years of follow-up. However, there is no data yet regarding the potential benefit of using nilotinib in the group of patients with suboptimal response. In this study, the efficacy of nilotinib 400mg BID will be compared to imatinib 600mg QD.
The comparative efficacy between imatinib dose escalation (600 mg QD) and nilotinib (400 mg BID), in terms of CCyR after 6 months, for patients with CML in chronic phase with suboptimal response to imatinib standard dose will be determined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Ph+ CML in CP defined as:
\<20% basophils in the peripheral blood;
•≥100x109/L (≥ 100,000/mm3) ;
SoR to 400 mg imatinib, defined as (min of 20 metaphases):
Parameters must be present:
Exclusion criteria:
4.Imatinib therapy started more than 12 months after the date of the original diagnosis; 5.Unable to tolerate imatinib at 400mg; 6.Previous treatment with any other tyrosine kinase inhibitor except Glivec and/or CML therapy other than IFN, hydroxyurea, and /or anagrelide; 7.Myelotoxicity ≥ Grade 2 present at the time of randomization, 8.Previously documented T315I mutations; 9.Impaired cardiac function including one of these:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 400 mg nilotinib twice daily (BID).
Drug: nilotinib
Participants received 600 mg imatinib once daily (QD).
Drug: imatinib
Percentage of Participants With Complete Cytogenetic Response (CCyR)
CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.
Time frame: 6 months
Percentage of Participants With Major Molecular Response (MMR)
MMR was defined as having a fusion gene of the Bcr and Abl genes of (BCR-ACL) less than or equal to 0.1% on the International Scale (IS).
Time frame: 12 and 24 months
Percentage of Participants With CCyr
CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.
Time frame: 12 and 24 months
Time to CCyR
Time to CCyR was defined as time from date of randomization to date of first documented CCyR.
Time frame: 24 months
Duration of CCyR
Duration of CCyR was defined as time from the date of ransomization to the date of first loss of CCyR or death, whichever came first.
Time frame: 24 months
Progression-Free Survival (PFS)
PFS was defined as the time from the date of randomization to the date of documented disease progression to accelerated phase or blast crisis (AP/BC), or death due to any cause.
Time frame: 24 months
Event-Free Survival (EFS)
EFS was defined as the time from the date of randomization to the date of the first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of Partial Cytogenetic Response (PCyR), loss of CCyR, death on treatment or progression to AP/BC.
Time frame: 24 months
Overall Survival (OS)
OS was defined as time from date of randomization to the date of the death.
Time frame: 24 months
Participants were randomized in 1:1 ratio to imatinib 600 mg QD or nilotinib 400 mg BID for a 2 year study period.
| Milestone | Nilotinib | Imatinib |
|---|---|---|
| Started | 96 | 95 |
| Full analysis set | 96 | 95 |
| Safety set | 96 | 93 |
| Cross-over set | 13 | 56 |
| Completed | 0 | 0 |
| Not completed | 96 | 95 |
| Withdrew: Administrative problems | 1 | 0 |
| Withdrew: Lost to follow-up | 2 | 1 |
| Withdrew: Death | 1 | 2 |
| Withdrew: Adverse event | 8 | 2 |
| Withdrew: Disease progression | 7 | 3 |
| Withdrew: Withdrawal by subject | 9 | 5 |
| Withdrew: Protocol deviation | 2 | 6 |
| Withdrew: Treatment duration completed | 66 | 76 |
CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.
| Percentage of participants | Nilotinib | Imatinib |
|---|---|---|
| Percentage of Participants With Complete Cytogenetic Response (CCyR) | 50.0 | 42.1 |
MMR was defined as having a fusion gene of the Bcr and Abl genes of (BCR-ACL) less than or equal to 0.1% on the International Scale (IS).
| Percentage of participants | Nilotinib | Imatinib |
|---|---|---|
| 12 months | 36.5 | 25.3 |
| 24 months | 37.5 | 35.8 |
CCyR was assessed from bone marrow samples. CCyr was defined as having 0% Philadelphia positive (Ph+) chromosome metaphases in bone marrow.
| Percentage of participants | Nilotinib | Imatinib |
|---|---|---|
| 12 months | 53.1 | 55.8 |
| 24 months | 51.0 | 61.1 |
Time to CCyR was defined as time from date of randomization to date of first documented CCyR.
| Months | Nilotinib | Imatinib |
|---|---|---|
| Time to CCyR | 5.55 (5.52 to 5.98) | 5.85 (5.59 to 11.04) |
Duration of CCyR was defined as time from the date of ransomization to the date of first loss of CCyR or death, whichever came first.
| Months | Nilotinib | Imatinib |
|---|---|---|
| Duration of CCyR | NA (NA to NA) | 17.2 (17.2 to NA) |
PFS was defined as the time from the date of randomization to the date of documented disease progression to accelerated phase or blast crisis (AP/BC), or death due to any cause.
| Months | Nilotinib | Imatinib |
|---|---|---|
| Progression-Free Survival (PFS) | NA (NA to NA) | NA (NA to NA) |
EFS was defined as the time from the date of randomization to the date of the first occurrence of any of the following: loss of Complete Hematological Response (CHR), loss of Partial Cytogenetic Response (PCyR), loss of CCyR, death on treatment or progression to AP/BC.
| Months | Nilotinib | Imatinib |
|---|---|---|
| Event-Free Survival (EFS) | NA (NA to NA) | 24.3 (23.8 to NA) |
OS was defined as time from date of randomization to the date of the death.
| Months | Nilotinib | Imatinib |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | 25.7 (NA to NA) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | — | 11/96 (11.5%) | 80/96 (83.3%) |
| Imatinib | — | 9/93 (9.7%) | 61/93 (65.6%) |
| Cross-over to Nilotinib | — | 4/56 (7.1%) | 44/56 (78.6%) |
| Cross-over to Imatinib | — | 1/13 (7.7%) | 11/13 (84.6%) |
| Event | Nilotinib | Imatinib | Cross-over to Nilotinib | Cross-over to Imatinib |
|---|---|---|---|---|
| TachyarrhythmiaCardiac disorders | 0/96 | 0/93 | 0/56 | 1/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/96 | 1/93 | 1/56 | 0/13 |
| Angina pectorisCardiac disorders | 2/96 | 0/93 | 0/56 | 0/13 |
| LymphadenopathyBlood and lymphatic system disorders | 0/96 | 0/93 | 1/56 | 0/13 |
| PneumoniaInfections and infestations | 0/96 | 0/93 | 1/56 | 0/13 |
| Blast cell crisisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/96 | 1/93 | 1/56 | 0/13 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/96 | 0/93 | 1/56 | 0/13 |
| EczemaSkin and subcutaneous tissue disorders | 0/96 | 1/93 | 1/56 | 0/13 |
| Autoimmune thyroiditisEndocrine disorders | 1/96 | 1/93 | 0/56 | 0/13 |
| Retinal detachmentEye disorders | 0/96 | 1/93 | 0/56 | 0/13 |
| Event | Nilotinib | Imatinib | Cross-over to Nilotinib | Cross-over to Imatinib |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 11/96 | 18/93 | 10/56 | 4/13 |
| HeadacheNervous system disorders | 14/96 | 6/93 | 8/56 | 4/13 |
| ThrombocytopeniaBlood and lymphatic system disorders | 19/96 | 24/93 | 13/56 | 3/13 |
| NeutropeniaBlood and lymphatic system disorders | 11/96 | 23/93 | 13/56 | 1/13 |
| LeukopeniaBlood and lymphatic system disorders | 10/96 | 22/93 | 9/56 | 0/13 |
| VomitingGastrointestinal disorders | 4/96 | 10/93 | 5/56 | 3/13 |
| RashSkin and subcutaneous tissue disorders | 22/96 | 4/93 | 9/56 | 1/13 |
| Alanine aminotransferase increasedInvestigations | 20/96 | 5/93 | 9/56 | 0/13 |
| Blood bilirubin increasedInvestigations | 13/96 | 1/93 | 11/56 | 0/13 |
| DiarrhoeaGastrointestinal disorders | 6/96 | 15/93 | 1/56 | 1/13 |
| Age, Continuous(Years) | Nilotinib | Imatinib | Total |
|---|---|---|---|
| Mean | 44.6 ± 14.47 | 44.2 ± 15.02 | 44.4 ± 14.75 |
| Sex: Female, Male(Participants) | Nilotinib | Imatinib | Total |
|---|---|---|---|
| Female | 42 | 37 | 79 |
| Male | 54 | 58 | 112 |
The record gives a start of May 2009, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2015, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →